CBChiara Lena Blomen

Chiara Lena Blomen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Chiara Lena Blomen has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Patient willingness to de-escalate adjuvant therapy based on predictive biomarker results in stage IIB-IIID melanoma: A cross-sectional survey

    by Chiara L. Blomen, Jana Kelpe, Julian Kött, Mareike Rutenkröger, Isabelle Scholl, Stefan W. Schneider, Christoffer Gebhardt

  • Open Access

    Cancer survivorship in malignant melanoma

    by Markus Reitmajer, Susanne Dugas‐Breit, Chiara L. Blomen, Elisabeth Livingstone, Max Schlaak, Markus V. Heppt, Michael M. Sachse, Madlen Hörold, Friedegund Meier, Sebastian Haferkamp, et al.

    Summary: Robust long‐term survival data have transformed the prognosis of metastatic melanoma. For combination therapy with immune checkpoint inhibitors (ICIs), 10‐year melanoma‐specific survival rates now exceed 50 %, and durable disease control is achievable in a substantial proportion of patients, including those with brain metastases. With increasing long‐term survival, chronic and late‐onset treatment‐related toxicities are becoming increasingly relevant. In particular, chronic immune‐related adverse events (irAEs) may persist after discontinuation of ICI therapy or emerge with delayed onset. These toxicities can significantly impair long‐term quality of life and often require ongoing management; endocrine toxicities, for example, may necessitate lifelong hormone replacement therapy. In addition to physical sequelae, survivors frequently experience psychosocial and financial burdens, difficulties returning to work, and concerns related to fertility and family planning. These multidimensional challenges highlight the growing importance of survivorship care in patients treated with ICIs. Systematic assessment of physical and psychosocial burden as well as health‐related quality of life, especially through patient‐reported outcomes, can support clinical decision‐making and individualized follow‐up strategies. Integrating these assessments into structured, multidisciplinary survivorship care models is essential to address the complex long‐term needs of melanoma survivors and to optimize outcomes beyond disease control.


  • Open Access

    Langzeit‐Krebsüberleben ( Survivorship ) beim malignen Melanom

    by Markus Reitmajer, Susanne Dugas‐Breit, Chiara L. Blomen, Elisabeth Livingstone, Max Schlaak, Markus V. Heppt, Michael M. Sachse, Madlen Hörold, Friedegund Meier, Sebastian Haferkamp, et al.

    Zusammenfassung: Für das metastasierte Melanom liegen inzwischen robuste Daten zum Langzeitüberleben vor; so beträgt unter kombinierter Therapie mit Immuncheckpointinhibitoren (ICI) im metastasierten Stadium die melanomspezifische 10‐Jahres‐Überlebensrate über 50 %. Auch für Patienten mit Hirnmetastasen ist dauerhafte Krankheitskontrolle inzwischen bei einem substantiellen Anteil der Patienten erreichbar. Mit zunehmendem Langzeitüberleben, insbesondere nach zuvor erfolgter Therapie mit ICI, rücken chronische und spät auftretende therapieassoziierte Toxizitäten vermehrt in den Fokus, insbesondere chronische irAEs, die auch nach Beendigung einer Therapie mit ICI persistieren oder auch erst beginnen können. Langzeittoxizitäten können die Lebensqualität nachhaltig beeinträchtigen und erfordern zum Beispiel bei endokrinologischen Toxizitäten mitunter eine lebenslange Substitution. Neben den unmittelbar physischen Aspekten, sind häufig psychosoziale und finanzielle Belastungen, Schwierigkeiten beim beruflichen Wiedereinstieg, sowie Aspekte der Familienplanung und Fertilität zentrale Survivorship‐Themen. Die systematische Erfassung sämtlicher psychosozialer und physischer Belasungen, sowie der Lebensqualität, insbesondere als patientenberichtetes Outcome unterstützt Therapieentscheidungen und Nachsorgeplanung und sollte Teil des multidisziplinären Survivorship‐Care ‐Konzeptes sein.


  • Open Access

    Erfolgreiche multimodale Therapie der CD30‐positiven follikulotropen Mycosis fungoides

    by Chiara L. Blomen, Inga Hansen‐Abeck, Andrea Baehr, Stefan W. Schneider, Christoffer Gebhardt, Nina Booken

  • Open Access

    Successful Multimodal Therapeutic Approach for CD30‐positive Folliculotropic Mycosis Fungoides

    by Chiara L. Blomen, Inga Hansen‐Abeck, Andrea Baehr, Stefan W. Schneider, Christoffer Gebhardt, Nina Booken

  • Open Access

    Identifying Cellular Immunodeficiency Through a Persistent Herpetic Whitlow

    by Chiara L. Blomen, Finn Abeck, Nina Booken, Ute Siemann‐Harms, Stefan W. Schneider

    Cutaneous infections caused by HSV are common, with the oral and genital mucosa being most frequently affected (1, 2). In individuals with immunodeficiency, HSV‐2 caused skin lesions may appear severe and unusual, or occur simultaneously with other skin diseases (3). We report on a patient who presented with painful peri‐ and subungual hypergranulation of digitus III, accompanied by ulceration, honey‐coloured crusts and seropurulent exudate. Immunohistochemistry and PCR confirmed HSV‐2 caused chronic herpetic whitlow. Simultaneously, Herpes zoster and seborrhoeic dermatitis were diagnosed, leading to a thorough evaluation for underlying immunosuppressive conditions. While belonging to the MSM (Men who have sex with men) community, the patient declined HIV‐testing. Fluorescence‐activated cell sorting (FACS) analysis revealed a substantial reduction in CD4+ T‐cells, indicating severe cellular immunodeficiency. Following in‐depth conversations, the patient revealed that he had not undergone HIV testing due to anxiety of a positive test result and the potential associated social stigma. After underlining the significance of HIV testing for his own health, the risk of transmitting a potential infection to others, and informing about modern antiretroviral treatment, the patient ultimately decided to undergo testing, leading to HIV diagnosis. Antiretroviral medication was initiated, resulting in a reduction of HIV viral load and an improvement in cellular immunity. This case report demonstrates the enduring HIV stigma, which can lead to fear‐driven avoidance in HIV testing. Healthcare professionals should approach patients' fears with empathy, while also underscoring the importance of disclosing one's HIV status to others.

  • Open Access

    Posttransplantation course after allogeneic stem cell transplantation in a patient with advanced mycosis fungoides—Balancing relapse and rejection

    by Inga Hansen‐Abeck, Chiara L. Blomen, Finn Abeck, Leopold Torster, Stefan W. Schneider, Nina Booken

    Treatment of advanced cutaneous T‐cell lymphoma (CTCL) can be challenging. To date, the only potentially curative treatment option for advanced CTCL is allogeneic hematopoietic stem cell transplantation. We report on a patient with mycosis fungoides who received allogeneic hematopoietic stem cell transplantation due to rapid progression of the disease. Eight months after transplantation, relapse as well as chronic graft‐versus‐host disease occurred. Therefore, we initiated different treatment modalities, including bexarotene, extracorporeal photopheresis, topical treatment as well as the Janus‐kinase‐inhibitor Ruxolitinib. Even though the patient experienced high morbidity due to the allogeneic hematopoietic stem cell transplantation, 3 years after he is still alive and reports good health‐related quality of life. With this case, we aim to demonstrate that the posttransplant course can be difficult, balancing between relapse and graft‐versus‐host disease. Nevertheless, patients can benefit in terms of survival and their health‐related quality of life. Therefore, allogeneic hematopoietic stem cell transplantation should be considered as a treatment option, especially for patients with advanced CTCL and poor prognosis.


  • Open Access

    Combination of Immune Checkpoint Inhibitors and Liver-Specific Therapies in Liver-Metastatic Uveal Melanoma: Can We Thus Overcome Its High Resistance?

    by Chiara L. Blomen, Julian Kött, Tabea I. Hartung, Leopold K. Torster, Christoffer Gebhardt

    Uveal Melanoma (UM) is a rare disease; however, it is the most common primary intraocular malignant tumor in adults. Hematogenous metastasis, occurring in up to 50% of cases, mainly to the liver (90%), is associated with poor clinical course and treatment failure. In contrast to dramatic benefits of immunotherapy in many tumor entities, as seen in cutaneous melanoma, immune checkpoint inhibitors (ICI) do not achieve comparable results in Metastatic UM (MUM). The aim of this study was to investigate whether the combination of ICI with liver-directed therapies provides a potential survival benefit for those affected. This retrospective, single-center study, including n = 45 patients with MUM, compared the effect of combining ICI with liver-directed therapy (“Cohort 1”) with respect to standard therapies (“Cohort 2”) on overall survival (OS). Our results revealed a significant survival difference between Cohort 1 (median OS 22.5 months) and Cohort 2 (median OS 11.4 months), indicating that this combination may enhance the efficacy of immunotherapy and thus provide a survival benefit. There is an urgent need for randomized, prospective trials addressing the combination of liver-directed therapies and various strategies of immunotherapy (such as ICI; IMCgp100; personalized vaccines) in order to establish regimens which finally improve the prognosis of patients with MUM.


  • Open Access

    Communication Processes about Predictive Genetic Testing within High-Risk Breast Cancer Families: A Two-Phase Study Design

    by Chiara Lena Blomen, Aliaksandra Pott, Alexander E. Volk, Lars Budäus, Isabell Witzel

    Background: The detection of a pathogenic variant in the BRCA1 or BRCA2 gene has medical and psychological consequences for both, affected mutation carriers and their relatives. This study analyzed the psychological impact of genetic testing and mutation-positive test result as well as associated family communication processes from the perspective of BRCA1 or BRCA2 mutation carriers and their family members.Methods: We conducted a two-phase study with explanatory sequential mixed methods design to understand the perspective of psychological process regarding genetic testing more efficiently. First, we analyzed a survey data of 79 carriers of a BRCA1 or BRCA2 mutation. Second, we conducted focus group interviews of 10 family members to deepen understanding of communication processes in high-risk families.Results: The average age of the BRCA1 or BRCA2 mutation carriers was 48 years, 58% had a history of cancer. The majority (64.6%) had general psychological distress independent of cancer diagnosis in the patients’ history. The point prevalence of depression was 16.9%. The main motives for undergoing genetic testing were desire for safety, prevention and risk assessment for the own children. The mutation carriers were satisfied with the decision to undergo genetic testing. Contrary to their subjective perception, the respondents' knowledge about those mutations was moderate. The familial communication was merely partially successful. In contrast to the high rate of disclosure to at-risk relatives (100%), the reported uptake of genetic testing among informed at-risk relatives was low (45.6%). In-depth focus group interviews with 10 family members revealed significant barriers to accessing genetic counseling including anxiety, uncertainty about the benefits of testing and the own cancer risk, particulary among males.Conclusion: The detection of a BRCA1 or BRCA2 mutation has psychological impact not only on mutation carriers but also on their family members. An adequate knowledge of the genetic background is required to reduce the level of psychological distress and to support the familial communication process. Therefore, the quality of information sources for affected individuals and relatives and also the awareness of health care professionals have to be improved.